Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Cardiovascular Risk Prevention in a Canadian Population of Patients with Giant Cell Arteritis

YAN YEUNG and LILLIAN J. BARRA
The Journal of Rheumatology December 2017, 44 (12) 1942-1943; DOI: https://doi.org/10.3899/jrheum.170100
YAN YEUNG
Department of Medicine, Division of Rheumatology, St. Joseph’s Health Care London, Western University, London, Ontario, Canada.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LILLIAN J. BARRA
Department of Medicine, Division of Rheumatology, St. Joseph’s Health Care London, Western University, London, Ontario, Canada.
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lillian.barra@sjhc.london.on.ca
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Giant cell arteritis (GCA) is a large-vessel vasculitis with a predilection for cranial arteries. Based on retrospective studies, GCA is associated with an increased prevalence of traditional cardiovascular (CV) risk factors and CV events, including myocardial infarction and stroke1,2,3,4,5. However, studies regarding management of CV disease (CVD) in GCA are lacking. We report here on CV risk factors and CV complications, and describe physician adherence to guidelines for prevention of CV events in a Canadian population with GCA.

We studied a single-center retrospective cohort of patients with GCA assessed at the St. Joseph’s Health Care rheumatology clinic in London, Ontario, by rheumatologists between 2006 and 2015. Patients were identified by diagnostic codes, met American College of Rheumatology classification criteria for GCA, and had at least 1 followup visit. CV complication (CVC) was defined as a composite outcome: any acute coronary syndrome (ACS), stroke, transient ischemic event, or severe peripheral vascular disease (PVD) requiring surgical intervention. Ethics approval was given by the Western University Health Science Research Ethics Board (approval #18683E).

The complete electronic medical record was reviewed. The following data were collected: presenting features and management of GCA, CV risk factors, medications at diagnosis and last followup, Framingham risk score, and CVC at any time during followup. At last followup visit, adherence to recommended primary and secondary prevention for CVD was based on the 2009 Canadian Cardiovascular Society guidelines6. Seventy patients were included: 53 females (76%) and 17 males (24%) with mean age 72 years (SD 8.0) at GCA diagnosis, median followup 31 months (range 1–175; 17,260 person-yrs). Most common presenting features of GCA were headache (82%), jaw claudication (41%), polymyalgia rheumatica (38%), visual disturbance including blindness (37%), and scalp tenderness (37%). At diagnosis, GCA was managed with high-dose prednisone at a median dose of 50 mg (range 30–100) in all patients. Over the followup period, 57% received adjunctive immunosuppression in combination with prednisone: methotrexate (47%), leflunomide (4%), cyclophosphamide (4%), rituximab (1%), and hydroxychloroquine (1%). Adjunctive immunosuppression was higher compared to another large cohort7.

A large proportion of patients had CV risk factors or CVC prior to GCA diagnosis: hypertension (57%), hyperlipidemia (53%), current/prior cigarette smoking (30%), diabetes (13%), and CVC (6%; Table 1). At diagnosis, 44% of patients were previously receiving or started on an antiplatelet/anticoagulant (AP/AC) drug.

View this table:
  • View inline
  • View popup
Table 1.

Cardiovascular risk factor prevalence and management in GCA.

At last followup, 93% continued to take prednisone with a median daily dose of 5 mg (range 0–80 mg); 4 patients were taking high-dose prednisone (60–80 mg daily), 2 because of GCA flare, and 2 were seen soon after their diagnosis and initiation of high-dose prednisone. The prevalence of CV risk factors increased over the followup period (Table 1). Fifteen patients (21%) had a CVC (7 ischemic strokes, 3 ACS, and 5 severe PVD). There were 7 deaths (2 sepsis, 1 lung cancer, 1 bowel perforation, 3 unknown). At last followup, 54% of all patients were prescribed AP/AC. Of the patients who had a CVC, 20% did not receive the recommended AP/AC for secondary CVC prevention. Framingham risk stratification was performed in 59% of patients within 24 months of the last followup; of those patients, 21% were not taking a lipid-lowering agent when indicated.

Overall, our study highlights several issues. Prevalence of CVC and CV risk factors was high: > 50% of patients with GCA had at least 1 traditional CV risk factor at baseline, which increased over the followup period. Consistent with prior studies, CVC (particularly stroke) was common after a diagnosis of GCA1,2,3,4,5. Low-dose aspirin has been recommended for stroke prophylaxis8, but only half of the patients were taking an AP/AC. There are no controlled trials for the use of AP/AC in GCA9, which may partially explain this finding. Even in patients who had a CVC, AP/AC use for secondary prevention was 80%, and guideline-based statin therapy by Framingham risk stratification was administered to only 59% of patients; of those patients, 21% were not taking a statin when recommended by guidelines6 (Table 1).

Our study also raises questions about why CVC prevention might be low in this population. Lack of allied-health professionals trained to assess CVC risk in clinic may have contributed. Other factors include lack of physician awareness about CVC risk in GCA, issues regarding the scope of practice and time constraints in rheumatology, and/or diffusion of responsibility for CVC management among the various specialties involved. CVC risk factors should be identified by rheumatologists and addressed with other physicians in a shared-care model. Patient-specific factors include pill burden, education, and medication adherence/intolerance. Some may have had contraindications/intolerance to AP/AC or statins not mentioned in the medical record. Other limitations include possibly incomplete records, particularly for over-the-counter aspirin. Data regarding atrial fibrillation, which can cause ischemic stroke requiring anticoagulation, were not collected. Finally, the utility of the Framingham risk stratification tool in GCA is unclear. Ultimately, our study suggests that further quality improvement initiatives are needed to identify gaps in the management of CV risk and to improve outcomes in GCA.

REFERENCES

  1. 1.↵
    1. Amiri N,
    2. De Vera M,
    3. Choi HK,
    4. Sayre EC,
    5. Avina-Zubieta JA
    . Increased risk of cardiovascular disease in giant cell arteritis: a general population–based study. Rheumatology 2016;55:33–40.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Tomasson G,
    2. Peloquin C,
    3. Mohammad A,
    4. Love TJ,
    5. Zhang Y,
    6. Choi HK,
    7. et al.
    Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160:73–80.
    OpenUrlPubMed
  3. 3.↵
    1. Gonzalez-Gay MA,
    2. Piñeiro A,
    3. Gomez-Gigirey A,
    4. Garcia-Porrua C,
    5. Pego-Reigosa R,
    6. Dierssen-Sotos T,
    7. et al.
    Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 2004;83:342–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Duhaut P,
    2. Pinede L,
    3. Demolombe-Rague S,
    4. Loire R,
    5. Seydoux D,
    6. Ninet J,
    7. et al.
    Giant cell arteritis and cardiovascular risk factors: A multicenter, prospective case-control study. Arthritis Rheum 1998;41:1960–5.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Salvarani C,
    2. Della Bella L,
    3. Cimino P,
    4. Macchioni D,
    5. Formisano G,
    6. Bajocchi N,
    7. et al.
    Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 2009;48:250–3.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Anderson TJ,
    2. Grégoire J,
    3. Hegele RA,
    4. Couture P,
    5. Mancini GJ,
    6. McPherson R,
    7. et al.
    2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151–67.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mutatore F,
    2. Kermani T,
    3. Crowson C,
    4. Green A,
    5. Salvarani C,
    6. Matteson E,
    7. et al.
    Large-vessel giant cell arteritis: a cohort study. Rheumatology 2015;54:463–70.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mukhtyar C,
    2. Guillevin L,
    3. Cid MC,
    4. Dasgupta B,
    5. de Groot K,
    6. Gross W,
    7. et al.
    EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318–23.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Mollan SP,
    2. Sharrack N,
    3. Burdon MA,
    4. Denniston AK
    . Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev 2014;8:CD010453.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 44, Issue 12
1 Dec 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cardiovascular Risk Prevention in a Canadian Population of Patients with Giant Cell Arteritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cardiovascular Risk Prevention in a Canadian Population of Patients with Giant Cell Arteritis
YAN YEUNG, LILLIAN J. BARRA
The Journal of Rheumatology Dec 2017, 44 (12) 1942-1943; DOI: 10.3899/jrheum.170100

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Cardiovascular Risk Prevention in a Canadian Population of Patients with Giant Cell Arteritis
YAN YEUNG, LILLIAN J. BARRA
The Journal of Rheumatology Dec 2017, 44 (12) 1942-1943; DOI: 10.3899/jrheum.170100
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Owning Pets Reduces the Perception of Disease Activity in Patients With Rheumatoid Arthritis
  • Stepping Up Counseling and Referral to Effective Physical Activity Interventions for Adults With Osteoarthritis
  • Positive Temporal Artery Ultrasound and Biopsy After 5 Months of High-Dose Glucocorticoids
Show more letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2023 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire